skip to primary navigationskip to content

Understanding the stability of drug materials

last modified May 27, 2016 03:38 PM
TeraView licenses University of Cambridge patent to Support Drug Formulation in the Pharmaceutical Industry

Cambridge company TeraView has exclusively licensed a new University patent application pertaining to the formulation of drug ingredients using amorphous materials. This patent will assist TeraView's collaborations with leading pharmaceutical companies, which is helping to improve the speed of drug formulation, as well as the lifetime of drug products and their efficiency of manufacture.

The inventors of the new patent are Dr Axel Zeitler and Dr Juraj Sibik, from the Department of Chemical Engineering and Biotechnology at the University of Cambridge (Dr Sibik has since taken up a position at Roche in Basel, Switzerland). Their invention is a new method of using terahertz spectroscopy to investigate the stability of amorphous materials, which can be used as active ingredients in drugs in the pharmaceutical industry. Amorphous ingredients have the potential to increase bioavailability (absorption by the body) of poorly soluble drugs when administered orally in the form of tablets or capsules.

Commenting on the collaboration with TeraView, Dr Zeitler stated 'Our work on amorphous materials has proven to be of great interest to the scientific community, in both its applications to materials science as well as the terahertz spectroscopy methodology itself. We have also had substantial interest from pharmaceutical companies. Our long-standing relationship with TeraView, and its position as the leading provider of terahertz solutions, making TeraView a natural partner to make our invention available to the wider industrial community.'

Dr Phil Taday, a Principal Scientist and Head of Applications at TeraView, said of the agreement, 'Understanding the stability of amorphous materials is clearly of increasing importance to the pharmaceutical industry. TeraView sees this patent as an important addition to our portfolio, with interest shown already by major pharmaceutical companies.'

Dr Don Arnone, Chief Executive Officer of TeraView, commented: 'This agreement further solidifies our relationship with Dr Zeitler’s group, and we are proud to be associated with his work and that of his team. This collaboration, where we have provided TeraView systems and other means of support, is a very good example of the sort of collaboration we seek to establish with world experts in their fields, such as Dr Zeitler.'